The use of urine in the follow-up of HPV vaccine trials

References

• zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 1977; 78:1-30; PMID:202434
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, et al. A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions. Cancer Prevention Research 2009; 2:868-78; PMID:19789295; http://dx.doi.org/10.1158/1940-6207.CAPR-09-0031
   PubMed Web of Science ®Google Scholar
• The FUTURE II study group. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. New England Journal of Medicine 2007; 356:1915-27; PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741
   PubMed Web of Science ®Google Scholar
• Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines–immune responses. Vaccine 2012; 30(Suppl 5):F83-7; PMID:23199968; http://dx.doi.org/10.1016/j.vaccine.2012.04.106
   PubMed Web of Science ®Google Scholar
• Schiller JT, Castellsagué X, Garland SM. A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines. Vaccine 2012; 30(Supplement 5):F123-F38; PMID:23199956; http://dx.doi.org/10.1016/j.vaccine.2012.04.108
   PubMedGoogle Scholar
• Chatterjee A. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines 2014; 13:1-12; PMID:25256262
   PubMed Web of Science ®Google Scholar
• IARC. Primay end-points for prophylactic HPV vaccine trials. Working Group Report II Series. Lyon, 2014:1-94.
   Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, et al. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16–26 Years. Journal of Infectious Diseases 2009; 199:926-35; PMID:19236279; http://dx.doi.org/10.1086/597307
   PubMed Web of Science ®Google Scholar
• De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, Sanchez N, Schuind A. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28:6247-55; PMID:20643092; http://dx.doi.org/10.1016/j.vaccine.2010.07.007
   PubMed Web of Science ®Google Scholar
• Herrero R, Wacholder S, Rodríguez AC, Solomon D, González P, Kreimer AR, Porras C, Schussler J, Jiménez S, Sherman ME, et al. Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica. Cancer Discovery 2011; 1:408-19; PMID:22586631; http://dx.doi.org/10.1158/2159-8290.CD-11-0131
   PubMed Web of Science ®Google Scholar
• Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Brown DR, et al. Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women. Cancer Epidemiology Biomarkers & Prevention 2010; 19:1585-94; PMID:20530494; http://dx.doi.org/10.1158/1055-9965.EPI-09-1235
   PubMed Web of Science ®Google Scholar
• Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. The Lancet 2009; 373:1949-57; PMID:19493565; http://dx.doi.org/10.1016/S0140-6736(09)60691-7
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6//11//16//18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-66; PMID:17117182; http://dx.doi.org/10.1038/sj.bjc.6603469
   PubMed Web of Science ®Google Scholar
• Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, Prendiville W, Paraskevaidis E. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. 2008.
   Google Scholar
• Khallouf H, Grabowska A, Riemer A. Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines 2014; 2:422-62; http://dx.doi.org/10.3390/vaccines2020422
   PubMedGoogle Scholar
• Van Damme P. Phase I trial results with procervix vaccine in HPV 16/18 infected women with normal cytology. Abstract SS 9-4 Presented at EUROGIN Florence, Italy, 2013.
   Google Scholar
• Fambrini M, Penna C, Pieralli A, Bussani C, Fallani MG, Andersson KL, Scarselli G, Marchionni M. PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes after laser CO2 conization for high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2008; 109:59-64; PMID:18255129; http://dx.doi.org/10.1016/j.ygyno.2007.12.032
   PubMedGoogle Scholar
• Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, Minozzi S, Bellisario C, Banzi R, Zhao FH, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014; 15:172-83; PMID:24433684; http://dx.doi.org/10.1016/S1470-2045(13)70570-9
   PubMed Web of Science ®Google Scholar
• Cuschieri K, Nandwani R, McGough P, Cook F, Hogg L, Robertson C, Cubie H. Urine testing as a surveillance tool to monitor the impact of HPV immunization programs. J Med Virol 2011; 83:1983-7; PMID:21915874; http://dx.doi.org/10.1002/jmv.22183
   PubMedGoogle Scholar
• Vorsters A, Micalessi I, Bilcke J, Ieven M, Bogers J, Van Damme P. Detection of human papillomavirus DNA in urine. A review of the literature. Eur J Clin Microbiol 2012; 31:627-40; PMID:21818524; http://dx.doi.org/10.1007/s10096-011-1358-z
   PubMedGoogle Scholar
• Enerly E, Olofsson C, Nygard M. Monitoring human papillomavirus prevalence in urine samples: a review. Clin Epidemiol 2013; 5:67-79; PMID:23516174; http://dx.doi.org/10.2147/CLEP.S39799
   PubMedGoogle Scholar
• Kitchener HC, Owens GL. Urine testing for HPV. 2014.
   Google Scholar
• Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. 2014.
   Google Scholar
• Vorsters A, Van den Bergh J, Micalessi I, Biesmans S, Bogers J, Hens A, De Coster I, Ieven M, Van Damme P. Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. Eur J Clin Microbiol Infect Dis 2014; 33(11):2005-14; PMID:24916950
   PubMed Web of Science ®Google Scholar
• Vorsters A, Van Damme P, Clifford G. Urine testing for HPV: rationale for using first void. BMJ: BMJ, 2014; 349:g6252; PMID:25319476
   PubMed Web of Science ®Google Scholar